VACCINE

Vaccine • June 2011
Autoimmune hepatitis type 2
following anti-papillomavirus vaccination
in a 11-year-old girl
Author information
Della Corte C1, Carlucci A,
Francalanci P, Alisi A, Nobili V.
Unit of Liver Research
Department of Pathology
Bambino Gesù Children’s Hospital
IRCCS, P.le S. Onofrio 4, 00165 Rome, Italy
claudia.dellacorte@opbg.net
Abstract
In the last years numerous reports describing a possible association
between administration of vaccines and development of autoimmune
phenomena and overt autoimmune disease were published. Possible
mechanisms of induction of autoimmune phenomena by vaccines and
their excipients are probably similar to those implicated in induction
by infectious agents. Here we report the case of an 11-year-old girl
who developed autoimmune hepatitis type II after four weeks from
vaccination against human papillomavirus. The possible relationships
between the use of adjuvated vaccine against papillomavirus and autoimmune
hepatitis are discussed. Although we do not provide evidence
for a causal link, we suggest that the occurrence of the autoimmune
hepatitis may be related to the stimulation of immune system by adjuvated-vaccine,
that could have triggered the disease in a genetically
predisposed individual. Therefore a monitoring of liver function test
following administration of vaccine against papillomavirus may be
useful in adolescent girl with signs of hepatopathy, as jaundice, dark
urine or hepatomegaly, to early identify and to promptly treat autoimmune
liver disorders.
“In the last years
numerous reports
describing a possible
association between
administration of
vaccines and development
of autoimmune phenomena
and overt autoimmune
disease were published.”
http://www.ncbi.nlm.nih.gov/pubmed/?term=21596082